peoplePerson
Jae H. Park
Ran the long-term CD19 CAR-T studies in adult leukaemia that showed durable remissions and defined toxicity risk.
Led MSK's 19-28z CAR-T studies in adult B-ALL, showing that low disease burden at infusion predicts durable remission and lower toxicity, and now directs the cellular therapy service.
Role
Director, Cellular Therapy Service
Institution
Specialisms
CAR-T therapyAcute lymphoblastic leukaemiaCellular immunotherapy
Profiles
| Title | Journal | Year |
|---|---|---|
| Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia | New England Journal of Medicine | 2018 |
Pages like this
not linked directly; found by shared links- TrialFELIX
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- PersonRenier J. Brentjens
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- PersonNirali N. Shah
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- TrialTRANSCEND CLL 004
Shares CD19, CAR-T cell therapy.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares CD19, CAR-T cell therapy.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares CD19, CAR-T cell therapy.
- ProductBrexucabtagene autoleucel
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- TrialTOWER
Shares CD19, Acute lymphoblastic leukaemia.